GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » Float Percentage Of Total Shares Outstanding

Burning Rock Biotech (Burning Rock Biotech) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 19, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Burning Rock Biotech's float shares is 0.00 Mil. Burning Rock Biotech's total shares outstanding is 10.26 Mil. Burning Rock Biotech's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Burning Rock Biotech's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Burning Rock Biotech's Institutional Ownership is 7.33%.


Burning Rock Biotech Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Burning Rock Biotech's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/10.26
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burning Rock Biotech (Burning Rock Biotech) Business Description

Industry
Traded in Other Exchanges
Address
No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.